Dipeptidyl peptidase-4 (DPP-4) inhibitors such as linagliptin induce bullous pemphigoid in elderly diabetic patients. Stapokibart is a humanized monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor (IL-4Rα), used primarily for atopic dermatitis. The article describes a case of DPP-4 inhibitor-induced bullous pemphigoid in an elderly diabetic patient treated with Stapokibart injection. After treatment with Stapokibart, the patient's skin lesions completely disappeared. The treatment brought a significant improvement in the quality of life. No adverse reactions were reported. This case shows that Stapokibart can be an effective treatment for bullous pemphigoid induced by DPP-4 inhibitors.